Ibrutinib, Zanubrutinib, and NX-2127- Comparative Analysis

This assignment examines the effects of three BTK inhibitors, Ibrutinib, Zanubrutinib, and NX-2127 on platelet function and haemostasis. It highlights that Ibrutinib though effective in treating B-cell malignancies, disrupts platelet receptors and increases bleeding risk due to off-target effects. Zanubrutinib offers improved selectivity and less impact on platelets. The main focus is on NX-2127, a new BTK degrader using PROTAC technology, which selectively degrades BTK without affecting platelet receptor expression or viability. Laboratory results confirm that NX-2127 maintains platelet function and avoids cytotoxicity , making it a safer and more targeted alternative. The study supports NX-2127’s potential for clinical use and calls for further research into its long-term safety.